Multiple Myeloma Research Consortium
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Multiple Myeloma Research Consortium sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Multiple Myeloma Research Consortium: 4 sponsored US clinical trials, 2 recruiting.
Multiple Myeloma Research Consortium sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed/Refractory Multiple Myeloma, with 1 trials.
Upper-quartile sponsor footprint
Multiple Myeloma Research Consortium sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Horizon Two: HR NDMM (MMRC-100)
NCT07053436
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT04150965
Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03732703
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Multiple Myeloma Research Consortium pipeline
2 recruiting of 4 indexed (50% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Relapsed/Refractory Multiple Myeloma (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Multiple Myeloma Research Consortium: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Multiple Myeloma Research Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Multiple Myeloma Research Consortium page
4 registered trials is a research-attention snapshot, not an endorsement of Multiple Myeloma Research Consortium or any single study.
- 2 of Multiple Myeloma Research Consortium's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed/Refractory Multiple Myeloma is the condition Multiple Myeloma Research Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed/Refractory Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Multiple Myeloma Research Consortium pipeline card: 4 registered trials from official public datasets.Report a data error.